Pyxis Oncology, Inc. — Director's Dealing 2023

Sep 25, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Pyxis Oncology, Inc. (PYXS)
CIK: 0001782223
Period of Report: 2023-09-25

Reporting Person: Connealy Pamela Ann (CFO and COO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-09-25	Common Stock	P	12000	$1.6703	Acquired	804106	Direct

Footnotes

F1: Represents the weighted average purchase price of common stock purchased by the Reporting Person in open market transactions. The range of purchase prices on the transaction date was $1.615 to $1.70 per share. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased at each price.